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Abstract
Background : Non-invasive treatment is generally recommended for patients with non-specific 
chronic low back pain (CLBP). However, the impact of combination therapy with physical exercise 
and a serotonin-norepinephrine reuptake inhibitor has not been clarified in patients with non-specif-
ic CLBP. This study assessed the efficacy of combination treatment with exercise and duloxetine 
on non-specific CLBP and aimed to identify factors that contributed to improvement of LBP-induced 
disability.
Methods : This prospective study was conducted on consecutive outpatients with non-specific 
CLBP. Patients received a supervised home-based exercise program and duloxetine administration 
for 15 weeks. The Roland-Morris Disability Questionnaire (RDQ), Numerical Rating Scale (NRS), 
Hospital Anxiety and Depression Scale (HADS), and Pain Catastrophizing Scale (PCS) were as-
sessed at baseline and 15 weeks. Multiple logistic regression modeling was used to identify factors 
associated with an improvement in RDQ.
Results : Forty-two patients were enrolled. Overall, scores on the RDQ, NRS, and PCS (total 
score, magnification, helplessness) were significantly reduced at 15 weeks (p < 0.01 for all). An 
improvement of disability was confirmed in 22 patients (52%). A higher HADS depression score 
before and after the intervention was significantly associated with a lack of improvement in disability 
(p < 0.01). Further, a reduction in HADS anxiety score over 15 weeks was a significant factor as-
sociated with an improvement in disability (odds ratio : 1.99 ; 95% CI : 1.26-3.65).
Conclusions : Supervised exercise plus duloxetine resulted in favorable outcomes and an 
improvement of LBP-related disability in approximately 50% of patients. A reduction in anxiety 
over treatment was associated with the improved disability.
Key words : non-specific chronic low back pain, disability, duloxetine, physical exercise
Introduction
Chronic low back pain (CLBP) is a major health 
problem worldwide, with a lifetime prevalence of 
about 23%, and 11-12% of the population becoming 
disabled1). This persistent painful condition is as-
sociated with the development of multiple physical 
and psychosocial disabilities. Thus, strategies that 
focus on impaired physical activities as well as pain 
improvement are important in the treatment of 
CLBP.
Non-specific CLBP is defined as CLBP not at-
tributable to a recognizable, known pathoanatomical 
cause. Systematic reviews of randomized con-
trolled trials have reported on outcomes associated 
with various intervention strategies2-4). It is gener-
ally recommended that patients are treated with 
non-invasive interventions, including physical exer-
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cise, cognitive-behavioral therapy, patient education, 
mental healthcare, and use of therapeutic agents for 
non-specific CLBP. However, such interdisciplin-
ary approaches usually take place in a limited num-
ber of facilities for patients with intractable chronic 
pain.
Exercise programs have been found to be effec-
tive at reducing pain, improving physical function, 
and helping people return to work2,5,6). It has also 
been demonstrated that most exercise programs 
consist of individually designed, supervised pro-
grams, such as home-based exercises with regular 
follow-up visits to physical therapists7). In terms of 
pharmacologic therapies, oral non-steroidal anti-in-
flammatory drugs (NSAIDs) and opioids are used 
worldwide in the treatment of CLBP. However, 
long-term use of NSAIDs is associated with reno-
vascular, cardiovascular, and gastrointestinal risks.　
Thus, the lowest effective dose of an NSAID for the 
shortest period is recommended4). Strong opioids 
are generally considered a last resort due to the po-
tential for misuse, abuse, or addiction and should be 
reserved for cases in which all other pharmacologi-
cal options or alternative treatments have failed4).　
Duloxetine, a serotonin-norepinephrine reuptake in-
hibitor, is a unique analgesic that has recently been 
recognized to be an effective agent for treatment of 
CLBP without causing serious adverse effects8,9).　
Its pharmacological effects occur via modulation of 
the descending pain pathway, which is dysfunctional 
in patients with chronic pain conditions10). This 
mechanism, along with its good safety profile, lead 
us to believe that duloxetine may be better than con-
ventional analgesics in patients with CLBP.
It is therefore plausible that supervised physical 
exercise plus duloxetine could be a potentially opti-
mal treatment strategy in the primary outpatient 
setting. However, most systematic reviews high-
lighted the effectiveness of a single intervention ; 
few studies have assessed combination therapies of 
different types in patients with CLBP. We suggest 
that a combination of physical exercise and medica-
tion with proven benefits is a feasible and reasonable 
strategy for patients with disabling CLBP. The pri-
mary objectives of this study were to assess the im-
pact of combination therapy with supervised physi-
cal exercise and duloxetine administration on pain, 
disability, and psychologic distress and to identify 
factors that contribute to the alleviation of disability 
in patients with non-specific CLBP.
Materials and Methods
Participants and study design
This prospective study included consecutive 
patients diagnosed with non-specific CLBP at a sin-
gle hospital between February 2017 and February 
2019. Eligible patients were adults aged 30 to 79 
years who presented to our department with CLBP 
of at least 3 months’ duration. LBP was defined as 
a pain localized below the costal margin and above 
the inferior gluteal folds without symptoms of radic-
ular leg pain or numbness. The diagnosis was 
made by an orthopedic surgeon certified by the Japa-
nese Orthopaedic Association and the Japanese So-
ciety for Spine Surgery and Related Research.　
Plain radiographs and magnetic resonance imaging 
were used to assist in the diagnosis. Exclusion cri-
teria included malalignment of the lumbar spine, 
spondylolysis, spondylolisthesis, disc herniation, in-
fection, spinal compression fracture, and tumor.　
Spinal malalignment was defined as a coronal curva-
ture ≥ 10° Cobb angle or PI (pelvic incidence) - LL 
(lumbar lordosis) ≥ 10° while standing. Subjects 
were also excluded if they had a history of previous 
lumbar spine surgery ; severe cardiovascular, he-
patic, or renal disorders ; pregnancy ; gait distur-
bance requiring crutches or a walker ; any type of 
treatment for LBP within 1 month before the first 
visit ; cognitive impairment with obvious difficulty 
for self-reported questionnaires ; and a history of 
psychogenic disorders. Assessment for existence 
of psychological disorders was not conducted for 
study entry at first visit. The study protocol was 
approved by the institutional review board of our 
hospital (No. 17020101) and registered at a national 
clinical trial site (UMIN 000039713). We humbly 
confess delayed registration of this clinical trial, in 
part due to a lack of knowledge about registration 
protocols. Written informed consent was obtained 
from all eligible participants.
Interventions
Physical exercise
Rehabilitation and home exercise advice for 
self-care were provided by physiotherapists on a 
1-to-1 basis at the rehabilitation department’s out-
patient service. The exercise program focused on 
trunk muscle stretching and strengthening and was 
supplemented by a light aerobic warm-up such as on 
a stationary bicycle or treadmill. Stretching exer-
cises included a series of 5 static stretches focused 
on the abdominal and low back muscles, iliopsoas, 
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gluteal muscles, and hamstrings. Strengthening 
exercises consisted of maneuvers of abdominal 
draw-in for trunk flexors, and bridge and bird-dog 
for trunk extensors. Patients were required to at-
tend the program once a week or once in 2 weeks 
and advised to continue exercises at home for 15 
weeks. Home exercises consisted of 3 to 5 sets of 
5 to 10 repetitions for each aforementioned stretch-
ing and strengthening activity ; patients were en-
couraged to perform the exercises twice daily based 
on their ability. A brochure that featured pictures 
of each exercise was given to each patient to serve 
as a reminder of how to perform the exercises.
Duloxetine
Oral administration of duloxetine started from 
20 mg at bedtime for 1 week and increased to 40 mg 
after 1 week and then to a maximum of 60 mg over 
15 weeks. The maintenance dosage was adjusted 
individually with a flexible dosing approach, consid-
ering patients’ preferences and minimizing adverse 
drug reactions. Metoclopramide 5 mg/day was also 
administered prophylactically to reduce symptoms of 
nausea that could be caused by duloxetine. Partici-
pants underwent tapering of duloxetine after 15 
weeks. Additional therapies for pain relief exclud-
ing physical exercise were prohibited during the 
study.
Clinical outcome measurements
Clinical assessments were conducted by self-
reported questionnaires distributed by the nurse in 
charge of patients at the outpatient clinic before 
treatment and at 15 weeks after treatment. The 
Roland-Morris Disability Questionnaire (RDQ), 
which is recognized worldwide as a measurement of 
physical disability associated with activities of daily 
living (ADL) due to LBP11), was completed by all 
participants at both time points. The RDQ contains 
24 items that are not weighted, and scores range 
from 0 (no disability) to 24 (maximum disability).　
Higher scores indicate higher LBP-induced disabili-
ty regarding ADL. A reduction in score of >2 
points at 15 weeks was determined to represent a 
clinically meaningful improvement in ADL12).　
Based on this criteria, the participants were catego-
rized into 2 groups : responders (R) and non-re-
sponders (non-R).
Pain intensity was assessed using a numerical 
rating scale (NRS) for worst pain experienced during 
the past week. Scores were assessed on an 11- 
point scale, where 0 = no pain and 10 = worst imag-
inable pain. The Hospital Anxiety and Depression 
Scale (HADS) was used to evaluate the severity of 
anxiety and depression. The HADS contains 14 
items, 7 of which relate to anxiety (HADS-A) and 7 
of which related to depressive symptoms (HADS-
D).　Each item is scored from 0 to 3, and the total 
score ranges from 0 to 21. Higher scores indicate 
the presence of anxiety and/or depression. A score 
between 0 and 7 represents the absence of anxiety 
or depression ; a score between 8 and 10 suggests 
possible anxiety or depression ; a score ≥ 11 indi-
cates clinically significant anxiety or depression13,14).　
Pain catastrophizing was measured with the Pain 
Catastrophizing Scale (PCS), which contains 13 
items related to 3 factors : rumination (5 items), 
magnification (3 items), and helplessness (5 items).　
Each item is scored from 0 to 4, and the total PCS 
score ranges from 0 to 52. Higher scores indicate a 
greater level of pain catastrophizing.
Statistical analysis
The per-protocol analysis population included 
all subjects who completed the study protocol.　
Continuous variables are presented as mean ± SD.　
Categorical variables are presented as numbers.　
Demographic data were assessed using the χ2 test 
and the unpaired t-test. Differences in scores on 
NRS, HADS, and PCS between baseline and 15 
weeks were assessed using the Wilcoxon signed-
ranks test. The Mann-Whitney test was used for 
comparisons between the R and non-R groups.　
Variables with p values <0.1, which could represent 
factors involved in the improvement of disability, 
were assessed as independent variables by a simul-
taneous multivariate logistic regression analysis.　
Outcomes were reported as odds ratios (OR) with 
95% confidence intervals (CI). A p-value <0.05 
was considered statistically significant. Data were 
analyzed with JMP® software (SAS Institute Inc., 
Cary, NC, USA).
Results
A total of 42 patients (22 men and 20 women ; 
mean age, 62.6 ± 13.9 years) of 51 enrolled were in-
cluded in the per-protocol analysis. A mean dura-
tion of symptoms was 27.4 ± 18.5 months. Rea-
sons for discontinuation were as follows : lost to 
follow-up (n = 4), nausea (n = 2), somnolence (n = 
1), headache (n = 1), and appetite loss (n = 1), in-
cluding 9.8% (n = 5) duloxetine-induced adverse 
reactions (Figure 1). No serious adverse events 
occurred throughout the study. In terms of dulox-
etine dose, 15 patients received 20 mg/day, 17 pa-
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tients received 40 mg/day, and 10 patients received 
60 mg/day.
Efficacy of combined treatment
The RDQ and NRS scores were significantly 
reduced at 15 weeks (p < 0.01 for both ; Table 1).　
Psychological measurements showed that total PCS 
score, magnification score, and helplessness score 
were significantly reduced compared with baseline (p 
< 0.01 for all). Neither HADS-A nor HADS-D 
changed after the intervention.
Improvement of ADL by RDQ score was seen 
in 22 patients (52%, group R) ; the remaining 20 pa-
tients (group non-R) did not show any changes. No 
significant differences in demographic characteris-
tics were seen between the R and non-R groups 
(Table 2).　HADS-D scores in the non-R group 
were significantly higher than those in the R group 
before and after the intervention (p < 0.01 ; Table 
3). In terms of the changes in scores after inter-
vention (pre-post), a significant difference was found 
only in the HADS-A score in comparisons of groups 
(p < 0.01). There was a modest but insignificant 
difference in NRS score between groups (p = 
0.06). The multivariate regression analysis, where 
HADS-A and NRS scores were considered indepen-
dent variables based on results of univariate analy-
ses, revealed that a reduction in HADS-A score was 
a contributing factor for the improvement of LBP-
induced disability (OR : 1.99, 95% CI : 1.26-3.65, C 
statistic : 0.82 ; p < 0.01 ; Table 4).
Figure 1. Study flow diagram
 Of 51 eligible participants, four were lost to follow-up and five discontinued because of adverse effects of dulox-
etine. The remaining 42 participants completed this study.
Table 1. Overall treatment outcomes (n = 42)
Pre Post P
RDQ 7.8 ± 2.8 5.9 ± 3.1 <0.01
NRS 6.0 ± 1.3 4.6 ± 2.1 <0.01
PCS
 total score 26.9 ± 9.8 23.2 ± 10.1 <0.01
 rumination 13.4 ± 4.8 12.0 ± 4.0  0.09
 magnification 5.5 ± 2.7 4.3 ± 2.4 <0.01
 helplessness 8.1 ± 3.3 6.8 ± 3.8 <0.01
HADS
 anxiety 6.8 ± 3.9 6.8 ± 3.6  0.78
 depression 5.6 ± 2.8 5.5 ± 3.2  0.67
Notes : Values are presented as means ± standard devi-
ation
Abbreviations : RDQ, Roland-Morris Disability Ques-
tionnaire ;  NRS, Numerical Rating Scale ; PCS, Pain 
Catastrophizing Scale ; HADS, Hospital Anxiety and 
Depression Scale.
Table 2.  Comparisons of demographic data between 
groups
R Non-R P
Age (years) 63.6 ± 12.5 61.5 ± 15.4 0.62
Gender (M/F) 12/10 10/10 0.77








Notes : Variable data : mean ± standard deviation ;  cat-
egorical data : number of cases
Abbreviations : R, group of responders ; Non-R, group 
of non-responders ; BMI, body mass index.
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Discussion
Though various therapeutic strategies are avail-
able for CLBP, non-invasive interventions for non-
specific CLBP are preferred. Evidence based on 
meta-analyses and systematic reviews suggests that 
physical exercise alone has a positive influence on 
pain intensity, ADL, physical function, and psycho-
logical impairment2,6,15). Reduced scores in NRS 
and RDQ after intervention in this study support 
findings in these studies. A reduction in PCS score 
was seen in this study after intervention as well, and 
low levels of physical activity are closely related to 
high pain catastrophizing and fear-avoidance be-
liefs16,17). On the other hand, mental scores of anxi-
ety and depression, which are common comorbidi-
ties in patients with persistent pain conditions such 
as CLBP18,19), were relatively low to begin with and 
did not improve throughout the study as a whole.
Based on its efficacy and safety, duloxetine was 
used in this study to replace NSAIDs or opioids in-
cluding tramadol due to the potential adverse effects 
of these agents10). Duloxetine is approved by the 
Food and Drug Administration for diabetic neuro-
pathic pain, fibromyalgia, major depressive disorder, 
generalized anxiety disorder, and chronic musculo-
skeletal disorder and has been used for the same in-
dications except for generalized anxiety disorder in 
Japan. It is reported that duloxetine substantially 
reduces pain by acting directly on pain modulation 
rather than lifting depressive symptoms in patients 
with CLBP20). This underlying mechanism seems 
Table 3. Comparisons of changes in scores between groups
R Non-R P R Non-R P
Difference (pre-post)
NRS pre 6.1 ± 1.0 5.9 ± 1.6 0.99
post 4.2 ± 1.7 5.1 ± 2.4 0.15 1.9 ± 1.9 0.8 ± 2.1 0.06
PCS
 total score pre 25.9 ± 11.4 28.0 ± 7.8 0.47
post 22.2 ± 9.9 21.4 ± 10.4 0.41 3.7 ± 5.8 3.7 ± 8.9 0.72
 rumination pre 13.3 ± 4.8 13.5 ± 4.9 0.80
post 12.0 ± 3.4 12.0 ± 4.8 0.94 1.2 ± 2.7 1.5 ± 6.1 0.87
 magnification pre 5.3 ± 2.8 5.8 ± 2.6 0.53
post 3.8 ± 2.7 4.8 ± 1.9 0.23 1.5 ± 1.7 1.0 ± 1.5 0.27
 helplessness pre 7.6 ± 3.7 8.7 ± 2.7 0.45
post 6.5 ± 3.9 7.1 ± 3.7 0.59 1.2 ± 2.8 1.6 ± 2.0 0.69
HADS
 anxiety pre 6.8 ± 3.8 6.8 ± 4.1 0.97
post 6.0 ± 3.1 7.7 ± 4.0 0.24 0.8 ± 1.7 −1.0 ± 1.5 <0.01
 depression pre 4.2 ± 2.2 7.1 ± 2.7 <0.01
post 3.7 ± 2.4 7.5 ± 2.9 <0.01 0.5 ± 1.8 −0.35 ± 2.4 0.17
Notes : Values are presented as means ± standard deviation
Abbreviations : R, group of responders ; Non-R, group of non-responders ; NRS, Numerical Rat-
ing Scale ;  PCS, Pain Catastrophizing Scale ; HADS, Hospital Anxiety and Depression Scale.




SE Odds ratio 
(95% CI)
 P
d-NRS 0.24 0.19 1.27 (0.89-1.89)  0.20
d-HADS anxiety 0.69 0.27 1.99 (1.26-3.65) <0.01
Notes : C statistic : 0.82
Abbreviations : d-NRS, difference in Numerical Rating Scale ; d-HADS, 
difference in Hospital Anxiety and Depression scale ; SE, standard error. CI, 
confidence interval.
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toms.　The finding that therapeutic effects in the 
context of comparatively high scores in depression 
were hardly detectable might partly arise from the 
flexible dosing of duloxetine in the current study.　
Indeed, an average dose of 37.6 mg/day was lower 
than the fixed dose of 60 mg/day in previous studies 
in which duloxetine led to an improvement of de-
pression score in the patients with CLBP20,26).　It is 
well known that symptoms of depression are associ-
ated with poor prognosis regarding pain intensity, 
disability, health-related quality of life, chronicity, 
and labor productivity27-29). For selected patients 
with suspected or clinically significant depressive 
symptoms at the first visit, early intervention using 
a multidisciplinary approach with cognitive-behav-
ioral therapy might be superior to the treatment 
used in the current study.
Our study has some limitations. First, there 
was no control group for combined treatments.　Ex-
ercise therapies and medication are often provided 
at the same time for CLBP rather than monotherapy 
in orthopaedic clinics. Accordingly, prospective 
randomized studies comparing exercise plus dulox-
etine and exercise plus other pain-killers including 
weak opioids might be warranted to validate the 
benefit of duloxetine treatment. Second, adherence 
to prescribed home exercises was not investigated, 
and good adherence is considered to be associated 
with better clinical outcomes. Third, the treatment 
period was relatively short, and definitive outcomes 
for CLBP require long-term observations. Finally, 
symptom duration was 2.3 years on average in this 
study. It was reported that patients with ≥3 years 
of pain at baseline took a significantly longer time to 
improve than those with a shorter duration of pain30).　
However, even with these limitations, a combination 
of supervised exercises, which were continued at 
home, and duloxetine successfully led to an im-
provement of pain intensity, LBP-related disability, 
and pain catastrophizing over 15 weeks. The effec-
tiveness of this combination strategy on disability 
was seen in approximately half of subjects. The 
improved LBP-induced disability was relevant to a 
reduction of anxiety. To our knowledge, the com-
bined therapies of physical exercise and medication 
for CLBP have seldom been investigated in the last 
two decades. Considering such a paucity of evi-
dence, these new findings might be meaningful to 
help develop more appropriate strategies in the 
treatment of patients with non-specific CLBP.
to be due to activation of the descending inhibitory 
pain pathway, which leads to normalization of the 
dysfunctional process, a finding that is supported in 
rat neuropathic pain models21,22). The observed re-
duction in pain intensity might be partially explained 
by the duloxetine-induced analgesic effect, indepen-
dent of its antidepressant and anxiolytic effects.　
The most common adverse reactions associated 
with duloxetine include nausea, somnolence, dizzi-
ness, constipation, and dry mouth, most of which are 
mild or moderate in severity and occur in the initial 
phase of administration8,23). Adverse events leading 
to discontinuation in this study were observed in 5 
patients (9.8%), and this occurrence was lower than 
values reported in a double-blind, randomized con-
trolled study (13.9% for duloxetine 60-120 mg/day 
vs 5.8% for placebo)23). The lower rate of adverse 
events may be due to the lower dosing of 20-60 mg/
day in this study and the concomitant administration 
of metoclopramide.
Importantly, understanding characteristics of 
patients with CLBP should focus not only on pain 
but also on the impact of disability or interference 
with daily activities. One study reported a disasso-
ciation between severity of pain and disability in al-
most half of patients with LBP in which participants 
with a high level of disability despite only mild pain 
were older, felt more stress, were more depressed, 
and were less satisfied with working conditions 
compared with those with the opposite pattern24).　
Furthermore, regardless of pain intensity, a signifi-
cant association between RDQ score and medical 
care visit (medical clinic or complementary/alterna-
tive medical clinic) was reported in the patients with 
LBP25). Consequently, an exploration of factors as-
sociated with an improvement of LBP-induced dis-
ability allowed us to identify a potential therapeutic 
target. In the current study, changes in NRS re-
sulted in a small, insignificant association with an 
improvement of disability. This finding is thought 
to partly reflect the aforementioned potential disas-
sociation between LBP and disability. Interestingly, 
our results showed that only a reduction in anxiety 
during treatment was associated with amelioration 
of disability. This fact implies that anxiolytic care 
might be a crucial element of treatment when physi-
cal activities are impaired. In contrast, about half of 
our patients did not show any improvement in dis-
ability, and these patients had pronounced higher 
scores in depression at baseline compared with 
those with improvement in disability. This tenden-
cy lasted until endpoint, indicating that the treat-
ment strategy failed to reduce depressive symp-
154 A. Onda and M. Kimura
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